Research on the Countermeasures of Life and Health Industry in

Zhejiang Province under the Background of Common Prosperity

Zhijian Lin

, Can Huang

, Yinjiang Cui

1,*

, Fei Fang

, Qiufei Qiu

, Xiaolu Chu

and Guochang Lv

Zhejiang Institute of Scientific and Technological Information, Hangzhou 310006, China

The Institute for Intellectual Property Management, School of Management, Zhejiang University,

Hangzhou 310058, China

Keywords:

Life and Health Industry, Biomedicine, Traditional Chinese Medicine, Healthcare Service, Common

Prosperity, Zhejiang Province.

Abstract:

Life and health industry has the obvious advantages of long industrial chain, high technological content and

large market demand. It has gradually evolved into one of the key industries on which the states and regions

rely to seek sustainable development. It is also the golden card of Zhejiang Province's high-quality

construction of “common prosperity demonstration area”. Zhejiang Province has made remarkable

achievements in the development of life and health industry, forming regional characteristics in the fields of

biomedicine, traditional Chinese medicine, healthcare services. This paper analyzed the development

characteristics and shortcomings of life and health industry in Zhejiang province, and puts forward a new path

to promote the development of life and health industry in Zhejiang province from the aspects of park layout,

industrial clusters, R & D services, digital empowerment and innovation elements.

1 INTRODUCTION

The life and health industry is a general term for a

series of related products and services based on

medical health, biotechnology, and life science, with

the goal of serving people's health, including medicine

and medical equipment industry, health care industry

and health management service industry, etc. (Zhang,

2021) As a strategic emerging industry, life and health

industry has huge market potential, which will drive

the coordinated development of upstream and

downstream industries (Ge, 2020). In 2021, Chinese

President Xi Jinping called on China to promote

common prosperity in a context of high quality

development. Focusing on continuing steady increases

in income and high quality development, common

prosperity aims to increase the size of middle income

groups, raise the earnings of low income groups.

(Michael Dunford 2022) In recent years, Zhejiang

Province has always adhered to the guidance of

scientific and technological innovation, and has

developed an innovative development path for life and

health industry that meets the requirements of the

central government, is full of Zhejiang characteristics

Corresponding author

and meets the needs of the masses. Life and health

industry has gradually become the golden card of

Zhejiang Province's high-quality construction of

“common prosperity demonstration area”. In order to

explore the development status, effectiveness and

deficiencies of life and health industry in Zhejiang

province, this paper conducts extensive investigations

into the fields with significant regional characteristics

in Zhejiang Province, such as biomedicine, traditional

Chinese medicine and healthcare services. On this

basis, the countermeasures and suggestions for the

innovative development of life and health industry in

Zhejiang province under the background of common

prosperity are put forward.

2 CHARACTERISTICS OF LIFE

AND HEALTH INDUSTRY IN

ZHEJIANG PROVINCE

2.1 Biomedicine Industry

In 2020, the total industrial output value of

310

Lin, Z., Huang, C., Cui, Y., Fang, F., Qiu, Q., Chu, X. and Lv, G.

Research on the Countermeasures of Life and Health Industry in Zhejiang Province Under the Background of Common Prosperity.

DOI: 10.5220/0012020300003633

In Proceedings of the 4th International Conference on Biotechnology and Biomedicine (ICBB 2022), pages 310-318

ISBN: 978-989-758-637-8

 2023 by SCITEPRESS – Science and Technology Publications, Lda. Under CC license (CC BY-NC-ND 4.0)

biomedicine in the Zhejiang province reached 215.1

billion yuan, with an average annual growth rate of

12.6% during the 13th Five-Year Plan period. At

present, a total of 5 enterprises have been selected as

provincial "Eagle Action" cultivation enterprises, 15

have been rated as provincial "invisible champions",

and 50 listed enterprises which accounting for 1/7 of

the country. In general, the development of the

biomedical industry in Zhejiang province presents the

following characteristics.

(1) Chain development of characteristic parks to

promote the development and clustering of block

economy

The magnetic attraction effect of the province's

biomedical industry has gradually emerged. It has

developed into an industrial pattern composed of 2

"Ten Thousand Mu and One Hundred Billion"

platforms of Hangzhou Qiantang District

pharmaceutical port and Shaoxing Binhai New Area,

pharmaceutical parks such as Linping District

Biomedical High-Tech Park and Hangzhou Bay New

Area Life and Health Industrial Park, as well as

Pan'an "Jiangnan Pharmaceutical Town" and Yuhang

Digital Health Town. Among them, the

pharmaceutical port has introduced and cultivated

more than 1,400 biomedical enterprises, and seven of

the world's top10 biomedical enterprises have settled

down, with an annual output value of 39.4 billion

yuan and an annual growth rate of more than 15%.

(2) Innovation and development in key areas

strongly support the construction of Science and

Technology Innovation Highland

A number of key enterprises and blockbuster

achievements have been gathered in key areas such as

biological drugs, chemical drug preparations and

medical devices. In the field of small molecule

innovative drugs, Icotinib won the first prize of

National Science and Technology Progress Award in

2015. Ganovo, the first domestic anti hepatitis C

Class 1 innovative drug was developed, which broke

the monopoly of the United States. In the field of

advanced medical devices, the R&D of cutting-edge

products such as implantable heart valves and

cochlear implants is leading in the country.

Meanwhile, new business formats such as AI +

medicine and Internet + medical treatment continue

to emerge, and new therapies such as gene therapy

and cell therapy have made substantial progress. In

2021, a total of 8 preparations in the province were

approved by ANDA, accounting for 10% of national

total.

(3) "Rainforest-style" ecology takes initial shape,

consolidating the foundation of world-class industrial

landmarks

Zhejiang Province has integrated multiple

resources and built a complete full-chain industrial

innovation support system. It has deployed high-level

scientific research platforms such as West Lake

University and Zhijiang Laboratory, gathered leading

CXO companies such as WuXi Biologics and

Tigermed, integrated clinical resources such as the

First Hospital of Zhejiang University. By focusing on

clinical transformation needs, the R&D and

achievement transformation effectiveness were

effectively improved.

(4) The launch of innovative drugs and clinical

trials have both reached new records, and the

momentum of innovation and entrepreneurship is

good

The R&D and registration of innovative drugs in

Zhejiang Province are active. In 2021, the proportion

of R&D investment in the province's regulated

pharmaceutical enterprises to operating income is

4.9%, which is higher than the national average.

Zhejiang Province received a total of 69 production

approvals, including 3 innovative drugs and 66

generic drugs and a total of 79 clinical approvals were

obtained in this year, including 61 innovative drugs.

The number of innovative drugs listed and clinical

trials had both hit a record high.

2.2 Traditional Chinese Medicine

Industry

The traditional Chinese medicine (TCM) industry is

one of the seven historical classic industries in

Zhejiang Province, with the following characteristics.

(1) Industrial agglomeration is accelerating

Zhejiang province takes Hangzhou, Jinhua,

Quzhou and Lishui as the core, vigorously promotes

the regional characteristic TCM industry cluster. It

has built a number of "Zhejiang Eight Flavor"

standardized planting demonstration bases and

authentic TCM gardens, including the Jinhua natural

drug production base, Lishui characteristic TCM

production area, Pan'an "Jiangnan Medical Town".

The development pattern of modern TCM industry

with industrial agglomeration, regional linkage and

distinctive features has basically taken shape. Five

leading enterprises such as CONBA and Jolly

Pharmaceutical were selected into the top 100

National TCM list, and seven TCM enterprises such

as Shouxiangu were successfully listed (ranking first

with Guangdong province), forming a number of

TCM varieties that enjoy high popularity in China，

such as Kanglaite Injection, CORBRIN capsule and

Capsule Dendrobii.

Research on the Countermeasures of Life and Health Industry in Zhejiang Province Under the Background of Common Prosperity

311

(2) The protection and utilization level of

authentic local resources has been significantly

improved

Zhejiang province is a province with large TCM

resources, known as the "treasure house of medicinal

plants in southeast China". There are 2385 kinds of

TCM resources in the region, with reserves of more

than 1 million tons. The number and total amount of

authentic local resources rank second in China. It has

the only "Dapanshan National Nature Reserve" in the

country, which focuses on protecting the germplasm

resources of wild medicinal plants, and the "East

China Pharmaceutical Botanical Garden", with the

most abundant ecological types, and many TCM

resource protection parks or bases. During the "13th

Five-Year Plan" period, 8 new varieties of TCM

materials such as Zhejiang Fritillaria, Zhejiang

Ophiopogon japonicus, Dendrobium officinale, and

Ganoderma lucidum were cultivated by utilizing the

advantages of authentic germplasm resources, and the

number of new varieties was listed at the national

advanced level.

(3) The cultivation of the new "Zhejiang Eight

Flavor" has achieved remarkable results

Zhejiang province is one of the key producing

areas of TCM in China, and has always been praised

by the industry for its authentic quality and numerous

varieties, among which "Zhejiang Eight Flavor" and

the new "Zhejiang Eight Flavor" are the most famous.

In 2020, the planting area of traditional Chinese

medicinal materials in the province was 802,000 mu,

with a total output of 262,000 tons and a total

agricultural output value of 6.38 billion yuan, an

increase of 38.5%, 46.7% and 20.6% respectively

over 2015. Among them, the planting area of

"Zhejiang Eight Flavor" and new "Zhejiang Eight

Flavor" is 216,000 and 270,000 mu, and the actual

agricultural output value of Dendrobium candidum is

2.69 billion yuan, and the output value of

Dendrobium officinale reaches 2.69 billion yuan,

which has effectively promoted industrial efficiency

and farmers' income. It has established 73 provincial-

level "Authentic TCM Garden" demonstration bases,

and Pan'an Xinwo, Chun'an Linqi and Yueqing

Dajing have become the national TCM characteristic

town. The standardization and intensive production of

TCM have been significantly enhanced.

2.3 Healthcare Service Industry

The healthcare service industry in Zhejiang Province

developed earlier and achieved remarkable results,

showing the following characteristics.

(1) An elderly care service system of "home-

based, community-supported, institution-

supplemented, and combination of medical care and

nursing care" is initially formed

Zhejiang province has continued to innovate and

develop healthcare services, and promoted the reform

and innovation of healthcare services in accordance

with the three main lines of ensuring the bottom type

of elderly care, expanding inclusive elderly care and

supporting socialized elderly care. A set of policy

systems and mechanisms have been formed to

promote the development of business industries, and

a home-based, community-supported, institution-

supplemented, and combined with medical care has

been initially established (Huang, 2017; Wang, 2020;

Han, 2021). The overall development level of elderly

care services is among the top in the country, the

layout of elderly care facilities has been basically

completed, the elderly care service policy has been

initially established, and the development concept of

elderly care services has been significantly changed.

(2) Both the quantity and quality of healthcare

services have increased, becoming the main way to

build an "Common Prosperity" demonstration area

In recent years, the number of health care services

in Zhejiang Province has made historical

breakthroughs, and the quality of services has entered

the road of transformation. By the end of 2020, there

were 2,485 elderly care institutions with 475,500

beds, including 252,000 nursing beds, accounting for

53%, and 1,689 private elderly care institutions,

accounting for 70% of the total number of elderly care

institutions (Zhou, 2021). There are 1106 home-based

care service centers in Zhejiang province, covering

more than 75% of towns and sub-districts. 7,511

families of the elderly in difficulty have been

retrofitted for aging, with an excess of 10%

completed. 111 health care joint ventures have been

launched, distributed 11 cities in the province. In

terms of urban and rural basic old-age insurance, by

the end of 2020, 43.55 million people in Zhejiang

province participated in basic endowment insurance,

and 55.57 million people participated in basic

medical insurance (Statistical Science and Practice,

2021), and the "Zheli Yang" smart endowment

service platform was developed with a framework of

"1+5+N". The main indicators are in the forefront of

the country, and it has been supervised and

encouraged by the State Council for two consecutive

years. The healthcare service system has become the

main way to build a "Common Prosperity"

demonstration zone.

ICBB 2022 - International Conference on Biotechnology and Biomedicine

312

(3) The business model of elderly care services is

becoming clearer, and the enterprise track is

competitive

At present, Zhejiang's health care industry has

formed a relatively mature and diversified business

model, among which typical models include monthly

fee system, long-term rental single payment system,

membership system, property rights sales and

combination of financial products. Among them, the

monthly fee system is a typical business model

adopted by traditional elderly care institutions,

especially elderly care institutions that face just-in-

demand customers. The single-payment system for

long-term rentals is based on the monthly fee system.

Elderly care institutions receive a one-time fee for

beds ranging from 5 to 15 years, and thereafter,

according to the health status of the elderly, they

charge monthly nursing fees. The membership system

is an innovative model created by a large number of

companies entering the health care industry through

heavy asset investment. The elderly pay a certain

membership fee to lock in the rights to live in a senior

care institution, and then pay a monthly fee after

entering the senior care institution. Property rights

sales are the organic combination of the real estate

industry and the health care industry. After the

company sells the property rights of the old-age

housing, it provides old-age services to the elderly

and earns service fees on a monthly basis. The

combination of financial products means that the

elderly can purchase financial products, such as

insurance products or trust products, to lock in the

eligibility for occupancy in old-age institutions, and

enjoy insurance benefits and old-age services at the

same time (Anke Hassel, 2019; Gao, 2021). After

years of development, these five models have their

own advantages and disadvantages, and are suitable

for different types, backgrounds and positioning of

institutional pension projects.

3 DEFICIENCIES IN THE

DEVELOPMENT OF LIFE AND

HEALTH INDUSTRY IN

ZHEJIANG PROVINCE

3.1 Biomedicine Industry

(1) The magnitude and energy level of the industrial

cluster dimension needs to be further improved

In terms of cluster magnitude, the overall scale of

Zhejiang is less than that of Jiangsu and Shanghai,

and the gap will still be large in the future. In 2020,

the industrial scale of Zhejiang Province is 215.1

billion yuan, which is lower than Jiangsu's 448 billion

yuan. Suzhou proposed to build a world-class

biomedical industry landmark, and strive to exceed

400 billion yuan in 2025, which is twice the target of

Hangzhou. Shanghai proposed to double the

industrial scale during the "14th Five-Year Plan".

Zhejiang Province also lacks characteristic industrial

parks such as Shanghai Zhangjiang Medicine Valley,

Beijing Changping Zhongguancun Life Science Park

and Suzhou Biobay. In terms of the cluster level, the

layout and number of the national industrial clusters

in Zhejiang province need to be further increased. No

park in Zhejiang Province was selected into the Top

10 Comprehensive Competitiveness List of the "2020

China Biomedical Industrial Park Competitiveness

Evaluation and Analysis Report" released by the

China Biotechnology Development Center (see

Table1). Hangzhou High-tech Zone, the highest-

ranked in the province, only ranked 13th in the

country. In the "2021 Top 100 Biopharmaceutical

Industrial Parks" jointly released by CCID

Consulting's Pharmaceutical and Health Industry

Research Center and Sina Pharmaceuticals, only 3

parks in Zhejiang Province entered the Top50.

Hangzhou High-tech Zone ranked 18th in the list.

Table 1: List of national industrial clusters in the Yangtze River Delta.

Region

The strategic emerging

industry clusters of the

National Development

and Reform Commission

The innovative industrial clusters

pilot or cultivation of the Ministry

of Science and Technology

The advanced manufacturing

cluster of the Ministry of

Industry and Information

Technolo

Zhejiang

Hangzhou biomedicine / /

Jiangsu

Suzhou biomedicine

Kunshan RNAi Innovative Industrial

Clusters, Taizhou Biomedicine

Innovative Industrial Clusters,

Suzhou National High-tech Zone

Medical Device Innovative Industrial

Clusters (all pilots)

Shanghai

Pudong New Area

biomedicine

Zhangjiang Biomedical Industry

Cluster (cultivation Class)

Zhangjiang Biomedical

Industry Cluster

Research on the Countermeasures of Life and Health Industry in Zhejiang Province Under the Background of Common Prosperity

313

(2) The cultivation of innovation resources in the

dimension of industrial innovation needs to be further

improved

In terms of talent aggregation, Zhejiang Province

has 910 provincial talents in the field of biomedicine,

which is lower than 1,517 in Shanghai and 1,061 in

Jiangsu. In terms of enterprise innovation ability,

Zhejiang province has 10,460 key enterprises (with

products and patents), lower than 16,240 in Jiangsu

province. Shanghai is favored by international

leading enterprises. At present, 18 of the world's top

20 pharmaceutical companies and 17 of the top 20

medical device companies have set up the China

headquarters or R&D headquarters in Shanghai. In

terms of corporate financing capacity, the number of

biopharmaceutical companies in Zhejiang Province is

lower than that of Jiangsu, and less than half of

Shanghai. The disclosed amount is 23.75 billion

yuan, which is only 53.5% of Shanghai's 44.35 billion

yuan. Lack of innovation resources has resulted in the

weaker innovation ability of life and health

enterprises in Zhejiang Province, and the less leading

enterprises. In the list of China's top100

pharmaceutical enterprises, the number of Zhejiang

companies has dropped significantly due to the lack

of innovation capabilities, from 13 in 2004 to 9 in

2019. There are few leading biomedical funds in

Zhejiang Province. Hillhouse, Sequoia, and Lilly

Asia Ventures (LAV) and other international capital's

Chinese headquarters are located in Shanghai.

(3) Clinical research capacity is weak, and the

policy support for innovative drug research and

development needs to be further strengthened

From the perspective of research ability, the top

experts in clinical research of innovative drugs

mainly work in Beijing, Shanghai, Guangdong and

other places. Zhejiang Province lacks experts with

national influence, especially in the field of tumor

drug research that is currently the most concerned.

Moreover, the number of research results of Zhejiang

Province is significantly less than Jiangsu and

Shanghai. By 2020, the innovative drugs applied in

Jiangsu and Shanghai were 3.2 and 2.7 times that of

Zhejiang respectively, and the number of “third class

medical devices” were 2.1 and 1.3 times that of

Zhejiang respectively. From the perspective of

investment, the cost of clinical research accounts for

the majority of new drug research and development.

In order to attract high-quality projects, local

governments have launched policies to increase

clinical research support in recent years. For example,

Guangzhou will increase the reward amount by 50%

for new drug projects commissioned by the city's

institutions to carry out clinical trials, up to a

maximum of 15 million yuan. In Shanghai, the

maximum support for innovative drugs that carry out

Phase I, Phase II, and Phase III clinical trials in China

is increased to RMB 5 million, RMB 10 million, and

RMB 30 million respectively.

In contrast, Zhejiang's policy only specifies

development plans, such as "providing support

through provincial key R&D programs for innovative

drugs that companies obtain registration certificates

and realize production or sales, as well as new drugs

that have been registered in the United States or the

European Union." Wait. It can be seen that the clinical

research foundation in Zhejiang Province is relatively

weak, and the strength and breadth of clinical

research support for innovative drugs needs to be

further improved.

Table 2: List of enterprise innovation achievements in the Yangtze River Delta.

Achievements

Zhe

ian

Jian

su Anhui Shan

hai Ex

lain

Clinical a

lications

1708 5670 954 4651

Statistics by acceptance

number

As of 2020-12-31

Clinical applications

(innovative dru

383 1228 58 1387

Clinical trials

3029 5171 1707 4437

Statistics by registration

number

As of 2020-12-31

Clinical trials (innovative

dru

1014 1601 549 1572

Number of drugs

roved

5336 8760 4228 3141

Statistics by approval

number

As of 2020-12-31

Number of innovative

dru

s a

roved

8 42 5 10

Number of generic drugs

roved

4995 8086 4066 3012

Number of Class III

medical devices approved

829 1772 76 1096

According to the

registration certificate

statistics

As of 2020-12-31

ICBB 2022 - International Conference on Biotechnology and Biomedicine

314

3.2 Traditional Chinese Medicine

Industry

(1) The shortage of rural labor forces restricts the

production and cultivation of TCM

TCM industry is a labor-intensive industry. In

Zhejiang Province, the people engaged in the

cultivation of TCM are mainly the elderly, resulting

the prominent problems of labor shortage and

structural imbalance (Anke Hassel, 2019). This

restricts the large-scale development of TCM and

affects farmers' enthusiasm for planting. In addition,

TCM in Zhejiang are mainly planted in mountainous

areas. It is difficult to implement mechanical

replacement, and to popularize large-scale

machinery.

(2) Insufficient standardized management, heavy

metal and pesticide residues in some medicinal

materials exceed the standard

At present, China lacks pesticides suitable for

TCM, and there is little corresponding dose standard

"Chinese Pharmacopoeia" stipulates the limit

standard of 9 kinds of pesticide residues in TCM, but

the amount of pesticides used in production is far

greater than this number (Ma, 2018). It is the lack of

standards that makes it impossible to judge the real

situation of excessive pesticide residues in TCM. In

addition, there is also a problem that some pesticide

residue limits are too high. For example, in the

"Chinese Pharmacopoeia", the pesticide residue limit

of quinic acid is relatively high, which affects the

production and sales of Tongxiang Hangbaiju, and

also affects the market reputation.

(3) Insufficient production scale of Chinese patent

medicine

By 2020, there are 39 Chinese patent medicine

manufacturers and 76 decoction piece manufacturers

in Zhejiang province, accounting for 25% of the

pharmaceutical manufacturers. However, the revenue

and profit scale only account for 9.8% and 9.2% of

the drug production scale in the province,

respectively. In contrast, the revenue and profit of the

national TCM industry accounted for 29.1% and

25.0% of the pharmaceutical production,

respectively. Compared with other provinces, the

main business income of the processing of TCM

materials in Jiangsu Province alone reached 15.6

billion yuan, and the profit was 4.1 billion yuan,

which were 3.3 times and 13.2 times that of Zhejiang

Province respectively.

3.3 Healthcare Service Industry

(1) Insufficient implementation of policies and

relatively limited incentives

The government have introduced a large number

of policies and measures to encourage the

development of healthcare service industry, but the

implementation effect is not satisfactory. On the one

hand, the support policies of elderly care institutions

mostly focus on principle and macro guidance, and

lack specific implementation rules, which affects the

effectiveness of the policy to a certain extent. On the

other hand, the development of healthcare services

involves multiple departments, and there is a lack of

scientific and effective connection, interaction and

coordination mechanism between the policies of

different management departments, and sometimes

even falls into the embarrassing situation of mutual

preconditions, which affects the effective

implementation of policies (Huang, 2016). Compared

with public elderly care institutions, private

institutions are also faced with difficulties such as

lack of policy support and ineffective implementation

of support policies (Cui, 2017).

(2) High operating costs and insufficient sources

of funds

The construction costs, labor costs, maintenance

and management costs of various elderly care

services, the development and application costs of

smart and innovative elderly care products and

services, and the growing cost of personalized and

high-quality services are relatively high in Zhejiang

province. The imperfect capital security system,

including insufficient funding channels and low

capital operation efficiency, has become an important

reason for the lack of self-sustainable development

capabilities, operation difficulties, and inability to

achieve sustainable development of elderly care

enterprises, especially private elderly care

institutions. At the same time, there are problems of

policy arbitrage and serious deviation from the

original intention of the policy existing in some

investors.

(3) Lack of professional talents, and the level of

service standardization needs to be improved

The increase in the aging population has greatly

increased the demand for professional service

personnel in medical and health care, leisure health

care, trustee care, and domestic service. However, at

present, there is a relative shortage of professionals

and senior management talents such as doctors,

nurses, nutritionists, and rehabilitation specialists in

Zhejiang Province, and the service quality and

management level of the employees are not high

Research on the Countermeasures of Life and Health Industry in Zhejiang Province Under the Background of Common Prosperity

315

enough. Taking nursing care workers as an example,

there are only tens of thousands of people who have

obtained the professional qualifications of nursing

care in China, and less than 1,000 in Zhejiang

Province, which are far from meeting the pension

needs of different income groups in the society.

4 CONCLUSION

Based on the development status, effectiveness and

deficiencies presented above the conclusions are

obtained as below:

(1) Strengthen policy linkage and lead the layout

planning of the pharmaceutical park

The first, we should strengthen the guidance of the

layout and planning of pharmaceutical parks.

Establish a four-level work linkage mechanism of

province-city-district-park, and formulate the

development layout plan for the province's

biomedical industrial parks based on the development

foundation of each industrial park. The planning

should highlight the industrial characteristics of the

park, establish and improve the public service

platform and supporting upstream and downstream

enterprises, including intermediary service agencies.

The purpose is to promote industrial agglomeration,

enhance industrial service capabilities, build an

innovation and industrial ecosystem, and better attract

high-quality enterprises and projects. In addition,

attention should be paid to the development of high-

quality enterprises in the middle and late stages, and

individualized policy support and supporting services

should be provided for enterprises with the potential

to go public, so as to prevent the outflow of high-

quality enterprises in Zhejiang Province.

The second we should focus on advantages to

create a demonstration highland. Focus on increasing

support for regional parks with good industrial

foundation and characteristic advantages. For

example, the Yuhang Biomedical High-tech Park

located in Linping dstrict, with a total planned area of

21 square kilometers, has gathered more than 20

biopharmaceutical enterprises, including many

leading enterprises with wide coverage and strong

competitiveness. In particular, this park is close to

Shanghai and is in the core position of the Yangtze

River Delta metropolitan area. Under the situation of

comprehensively promoting the integrated

development of the Yangtze River Delta in the

province, it has strong advantages and potential. It is

recommended to give more attention and policy

support to such parks, and promote them to become a

first-class biomedical industry innovation highland in

the country.

(2) Focus on key areas, make overall planning and

construction of industrial parks to form a cluster

effect

The first is adhere to the leadership of leading

enterprises. Focus on the achievements of global

leading companies, industry invisible champions, top

talents in the industry and well-known scientific

research institutes in key fields such as

biopharmaceuticals, advanced medical device and

digital medicine, and increase efforts to introduce and

cultivate. With the help of the R&D innovation and

market development capabilities of key enterprises, it

will drive the improvement of innovation capabilities

of small and medium-sized enterprises and improve

the overall value chain.

The second is to guide the extension of the

industrial chain. We should carry out in-depth

industry-university-research cooperation, deploy

international frontier fields such as gene editing and

biomedical chips (Zhang, 2020). It is recommended

to make full use of the leading role of the provincial

scientific research special fund, encourage and guide

the resources and scientific research strength of

Zhejiang scientific research institutes, vigorously

support interdisciplinary research in the fields of

medicine, pharmacy, life science, artificial

intelligence, etc., and strengthen the joint effect of

government-industry-university-research.

(3) Focus on source innovation and build a first-

class R&D service system

The first is to speed up the overall system

infrastructure layout. Relying on research centers

such as West Lake University, Institute of Basic

Medicine and Oncology of the Chinese Academy of

Sciences, Liangzhu Laboratory, etc., and jointly with

Shanghai, Jiangsu and Anhui province, we should

commit to build advantageous disciplines and senior

talent think tanks. Deploy and construct major

scientific and technological infrastructure in frontier

fields such as brain science and synthetic biology in

advance, and strive to create national platforms.

Explore the establishment of a subversive technology

discovery funding mechanism to lead original

technological innovation breakthroughs.

The second is to innovate the full-chain

technological achievement transformation

mechanism. Accelerate the exploration of the

Zhejiang model for realizing the value of knowledge,

technology, data and other elements. Focus on

deepening the four-in-one cooperation of medical

institution, university, enterprise and financial

institution, establish an industrial technology

ICBB 2022 - International Conference on Biotechnology and Biomedicine

316

innovation alliance, open up the whole link of

production, education, research and medicine, and

promote the development of core technologies and

the transformation and application of achievements.

Strengthen joint technical research and application in

the prevention and treatment of major infectious

diseases such as COVID-19, tumors, and

cardiovascular and cerebrovascular diseases.

Encourage the research and development of

innovative TCM based on the Chinese classic

prescriptions. Accelerate the research and

development and industrialization of health care

products with TCM as raw materials, Chinese

medicine clinical diagnosis and treatment equipment,

and health care equipment (Jiao, 2018).

The third is to strengthen the construction of a

collaborative innovation platform for TCM. It is

necessary to establish a well-structured TCM

collaborative innovation system and mechanism, with

the national and provincial TCM scientific research

institutions as the core, with university, medical

institutions and TCM production enterprises as the

main body, and TCM scientific research bases and

TCM innovation platforms as the support (Bulletin of

The State Council of the People's Republic of China,

2016).

(4) Focus on digital empowerment, and develop

digital scenarios for the life and health industry

The first is to consolidate the resources of life and

health data and improve the analysis and computing

service capabilities. Zhejiang Province has strong

ability to process and analyze big data, but it is mostly

used in logistics and transportation fields, and the

application around life and health has just started. We

should further consolidate life and health data

resources, collaborate with existing digital life and

health-related institutions and innovation platforms,

bring together life and health digital resources and

technological advantages such as supercomputing

and digital processing, and build regional data

resource backup libraries to achieve upper and lower

linkages. It is necessary to break through the "stuck

neck" technologies such as high-performance

computing and mass storage, and realize the

application demonstration of digital life and health.

The second is to accelerate the integration of TCM

industry with advanced technologies such as big data,

Internet of things and blockchain. It is necessary to

combine big data, Internet of things, blockchain,

cloud computing, robotics and other technologies to

build an intelligent logistics system architecture for

Chinese herbal medicines, build a standardized,

intensive and traceable herbal medicine circulation

center for genuine herbal medicines, and promote

closer integration of the Internet of things system of

pharmaceutical circulation enterprises with the

quality traceability system (Jiao, 2018; Bulletin of

The State Council of the People's Republic of China,

2016). Chinese medicine hospitals at all levels are

encouraged to promote one-stop medical services

such as appointment registration, diagnosis and

treatment report and electronic prescription query, so

as to realize multi specialty joint diagnosis and

treatment through big data analysis and realize

precision medical treatment (Jiao, 2018).

The third is to enrich smart application scenarios.

It is necessary to further promote the digital reform of

healthcare services, and improve the ability of digital

service decision-making, service supervision, and

service supply and demand connection. Promote the

connection of healthcare service information with

information resources such as household registration,

medical care, social insurance, and social assistance,

improve the healthcare service payment system, and

realize a new leap in the digitalization of health care

services (Long, 2022; David, 2019; Pranav, 2021).

Health care service enterprises should make full use

of the smart elderly care information service

platform, undertake the content of elderly care

services purchased by the government, provide

professional and standardized services to the elderly

at home in the surrounding communities, and

establish a long-term mechanism for sustainable

development of the model (Han, 2021).

(5) Focus on the configuration of innovative

elements to build a full life cycle ecosystem

The first is to build a good ecological environment

for attracting and retaining talents. We should

optimize the ecological environment for innovation

and entrepreneurship, and speed up the construction

and improvement of biomedical parks. In terms of

taxation, house purchase, children's education and

other policies, it will be further refined according to

the talent levels to improve the attractiveness and

competitiveness of the policy. For example,

Hangzhou introduced a special reward policy for

high-level talents in November 2020. For qualified

high-level talents’ personal income tax, the portion

exceeding 15% will be rewarded by 80%-100% by

classification. After the implementation of the policy,

the social response has been good, and it is

recommended to promote it throughout the province,

and further increase the intensity and scope of tax

relief.

The second is to consolidate the intellectual

support of talents. We should vigorously implement

the "Kunpeng Plan" for top talents, draw a talent map

for the global life and health industry. It is necessary

Research on the Countermeasures of Life and Health Industry in Zhejiang Province Under the Background of Common Prosperity

317

to improve the talent supporting system and optimize

the "targeted and precise talent service". Focus on the

introduction and identification of professional service

and financial talents to ensure the talent needs of life

and health enterprises in the province. In addition,

policies should be formulated to encourage

enterprises to cultivate and introduce talents

spontaneously.

The third is to improve the construction of the

financial system. Provincial, municipal and district

governments should set up special industrial funds to

guide and gather domestic and foreign leading social

capital into Zhejiang. Learning from Shanghai

Zhangjiang Venture Capital, Suzhou Yuanhe Origin,

etc., we should cultivate and build local professional

life and health funds with national influence, and

improve the investment and financing system of the

province's life and health industry.

ACKNOWLEDGMENTS

This work was financially supported by the National

Office for Philosophy and Social Sciences through

grant no. 21AZD010.

REFERENCES

Anke Hassel, Marek Naczyk. (2019) The political economy

of pension financialisation: public policy responses to

the crisis. Journal of European Public Policy,26(4):

483-500.

Cui Shuyi, Tian Yang. (2017) The "bottleneck" of the

development of elderly care institutions and their

solutions——based on a survey of 45 elderly care

institutions in Shandong province. Chinese Population

Science, 02: 115-125+128.

David C Mainenti. (2019) Big data and traditional Chinese

medicine: (TCM) What’s state of the art. 2019 IEEE

International Conference on Big Data (Big Data):1417-

1422.

Gao Yue, Yan Zhang. (2021) The current situation of the

development of domestic and international wisdom

pension service products and models. ISAIMS 2021:

Proceedings of the 2nd International Symposium on

Artificial Intelligence for Medicine Sciences: 252–256.

Ge Yanfei, Shen Junlong, Li Jie, et al. (2020)

Implementation Mechanism of Economic Value of

Traditional Chinese Medicine Under the Vision of the

Great－health Industry. Medicine and Society,33(06):

38-41+52.

Han Ye, Ji Ran, Fu Jiaping. (2021) Research on the

dilemma and countermeasures of the sustainable

development of private elderly care institutions.

Demographic Journal, 43(04): 89-97.

Huang Zhenzhen. (2017) Zhejiang Province strengthens the

construction of urban and rural home care service

centers. Zhejiang Daily, 2017-03-04: 007

Huang Chuang. (2016) Operation of private pension service

institutions: Self-development and support system.

Chongqing Social Sciences, 02: 66-72.

Jiao Yunlong. (2018) Promote the high-quality

development of Zhejiang characteristic TCM industry.

Zhejiang economy, 05: 52-53.

Long Y, Chu D, Wang H, et al. (2022) Blockchain-based

trace the source system for Chinese medicinal

materials. The 14th international conference on

measuring technology and mechatronics automation

(ICMTMA): 1007-1010.

Ma Lei, He Bowei, Xu Danbin. (2018) Zhejiang Province

Traditional TCM Industry Development Report. Rural

Science Experiment, 09: 107-109.

Michael Dunford. (2022) The Chinese Path to Common

Prosperity, International Critical Thought, DOI:

10.1080/21598282.2022.2025561

Notice of the state council on printing and distributing the

outline of the strategic plan for the development of

TCM (2016-2030) [J]. Bulletin of The State Council of

the People's Republic of China, 2016(08): 21-29

Pranav Ratta, Amanpreet Kaur, Sparsh Sharma, et al.

(2021) Application of blockchain and Internet of things

in healthcare and medical sector: applications,

challenges, and future perspectives. Journal of Food

Quality, 1:1-20.

Wang Wenxi. (2020) Report on the construction of the

provincial elderly care service system. Zhejiang

National People's Congress (Bulletin edition), 04: 128-

131.

Zhang Yiyi. (2021) Research on the Development of Life

and Health Industry in Wuxi Taihu Bay Science and

Technology Innovation Belt. Statistical Theory and

Practice,10: 43-46.

Zhou xiang, Zhu Xudong. (2021) The "13th Five-Year

Plan" of Zhejiang Province civil affairs work

documentary. Zhejiang Daily, 2021-01-19:009.

Zhejiang Province National Economic and Social

Development Statistical Bulletin. (2021) Statistical

Science and Practice, 03: 4-11.

Zhang K, Liu W. (2020) The Current status, trend, and

development strategies of Chinese biopharmaceutical

industry with a challenging perspective. SAGE

Open,10(1):1582440209.

ICBB 2022 - International Conference on Biotechnology and Biomedicine

318